Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Considers Sponsoring Rare Drugs Through First Two Trial Phases

This article was originally published in PharmAsia News

Executive Summary

An arm of India's government proposes public funding of early-stage clinical trials if they are conducted at 11 national institutes. The Department of Pharmaceuticals proposes the National Institutes of Pharmaceutical Education and Research receive the funding to focus on developing new drugs for neglected diseases. Under the plan, the government would assist Phase I and Phase II trials to help spur a part of the drug-development process that has the most risk. After surviving the first two trial phases, NIPERS would hand the drug or treatment to private industry to develop further in Phase III trials. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel